Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: Is there a preferred regimen?

被引：24

作者：

Einhorn, LH ^{[1
]}

Foster, RS

机构：

[1] Indiana Univ, Dept Med, Indianapolis, IN 46204 USA

[2] Indiana Univ, Dept Urol, Indianapolis, IN 46204 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 16期

关键词：

D O I：

10.1200/JCO.2006.05.6184

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2597 / 2598

页数：2

共 50 条

[1] Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: Is there a preferred regimen? Reply
Kondagunta, GV
Motzer, RJ
Bosl, GJ
Sheinfeld, J
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2598 - 2599
[2] Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors
Funt, Samuel A.
McHugh, Deaglan J.
Tsai, Stephanie
Knezevic, Andrea
O'Donnell, Devon
Patil, Sujata
Silber, Deborah
Bromberg, Maria
Carousso, Maryann
Reuter, Victor E.
Carver, Brett S.
Sheinfeld, Joel
Motzer, Robert J.
Bajorin, Dean F.
Bosl, George J.
Feldman, Darren R.
ONCOLOGIST, 2021, 26 (06): : 483 - 491
[3] Cisplatin, etoposide and bleomycin infusion (PEBi regimen) in good-risk patients with germ cell tumors
Colleoni, M
Graffeo, R
Martinelli, G
Ghielmini, M
DeBraud, P
Zampino, G
Marini, G
Cavalli, F
Goldhirsch, A
ONCOLOGY REPORTS, 1997, 4 (05) : 913 - 916
[4] Cisplatin, etoposide and bleomycin infusion (PEBi regimen) in good-risk patients with germ cell tumors
Colleoni, M
Graffeo, R
Martinelli, G
Ghielmini, M
Marini, G
Cavalli, F
Goldhirsch, A
EUROPEAN JOURNAL OF CANCER, 1997, 33 : 176 - 176
[5] Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors
Kondagunta, GV
Bacik, J
Bajorin, D
Dobrzynski, D
Sheinfeld, J
Motzer, RJ
Bosl, GJ
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9290 - 9294
[6] Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial
Culine, S
Theodore, C
TerrierLacombe, MJ
Droz, JP
JOURNAL OF UROLOGY, 1997, 157 (03): : 855 - 858
[7] CISPLATIN-ETOPOSIDE AND CARBOPLATIN-ETOPOSIDE INDUCTION CHEMOTHERAPY FOR GOOD-RISK PATIENTS WITH GERM-CELL TUMORS
TJULANDIN, SA
GARIN, AM
MESCHERYAKOV, AA
PEREVODCHIKOVA, NI
GORBUNOVA, VA
SOKOLOV, AV
LJUBIMOVA, NV
MIRONOVA, GT
MOLCHANOV, GV
OZOLS, RF
HAMILTON, JM
ANNALS OF ONCOLOGY, 1993, 4 (08) : 663 - 667
[8] Combination of bleomycin, etoposide and cisplatin (BEP) versus etoposide and cisplatin (EP) in patients with good risk nonseminomatous germ cell tumors (NSGCT)
Tryakin, A.
Fedyanin, M.
Bulanov, A.
Titov, D.
Mitin, A.
Sergeev, J.
Figurin, K.
Fainstein, I.
Matveev, V.
Zakharova, T.
Kostjakova, L.
Garin, A.
Tjulandin, S.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S515 - S515
[9] A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors
Bokemeyer, C
Kohrmann, O
Tischler, J
Weissbach, L
Rath, U
Haupt, A
Schoffski, P
Harstrick, A
Schmoll, HJ
ANNALS OF ONCOLOGY, 1996, 7 (10) : 1015 - 1021
[10] RANDOMIZED TRIAL OF ETOPOSIDE AND CISPLATIN VERSUS ETOPOSIDE AND CARBOPLATIN IN PATIENTS WITH GOOD-RISK GERM-CELL TUMORS - A MULTIINSTITUTIONAL STUDY
BAJORIN, DF
SAROSDY, MF
PFISTER, DG
MAZUMDAR, M
MOTZER, RJ
SCHER, HI
GELLER, NL
FAIR, WR
HERR, H
SOGANI, P
SHEINFELD, J
RUSSO, P
VLAMIS, V
CAREY, R
VOGELZANG, NJ
CRAWFORD, ED
BOSL, GJ
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) : 598 - 606

← 1 2 3 4 5 →